Ocular Masthead Background

Board of Directors

Adrienne Graves, Ph.D.

Adrienne Graves, Ph.D.

Director

A visual scientist by training and a global industry leader in ophthalmology, Dr. Graves brings extensive experience to her role. As the former CEO of Santen Inc., the US subsidiary of a 130-year-old Japanese pharmaceutical company, she successfully established a strong global presence, bringing multiple ophthalmic products through development to approval and commercialization and leading global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Sr. VP of Worldwide Clinical Development (US, Europe, and Japan) for seven years and subsequently as CEO for eight years. Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in research and development, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology. Dr. Graves currently serves as a director on the boards of Greenbrook TMS Inc.; Qlaris Bio, Inc.; Nicox S.A.; NVasc, Inc.; Surface Ophthalmics, Inc.; and Opus Genetics, Inc. She previously served as Chairman of the Board of IVERIC bio, Inc. and held board positions at TherOptix, Inc.; Encore Vision, Inc.; Envisia Therapeutics, Inc.; Oxurion NV; TearLab Corporation (now Trukera Medical); Aerpio Therapeutics, Inc.; and Akorn, Inc. She serves on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB) and the RD (Retinal Degeneration) Fund. Dr. Graves also co-founded Glaucoma 360 and OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders). Dr. Graves received an A.B. with Honors in Psychology from Brown University, a Ph.D. in Psychobiology from the University of Michigan, and she completed a Postdoctoral Fellowship in Visual Neuroscience at the University of Paris. She is a Visionary Innovation Mentor at the Ophthalmic Innovation Program at Stanford University.